Eun Yang
Stock Analyst at Jefferies
(0.54)
# 4,174
Out of 5,143 analysts
31
Total ratings
35.29%
Success rate
-22.98%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $34.26 | +22.59% | 1 | Nov 5, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $474.52 | -8.96% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $4.84 | +65.29% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $56 → $12 | $5.50 | +118.18% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $67.91 | -51.41% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.28 | +2,087.50% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $27.45 | -1.64% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $1.88 | +272.34% | 1 | Feb 10, 2023 | |
| PRME Prime Medicine | Initiates: Buy | $25 | $3.34 | +648.50% | 1 | Nov 14, 2022 | |
| NCNA NuCana | Maintains: Buy | $105,000 → $15,000 | $2.06 | +728,055.34% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.45 | +1,624.14% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $25.49 | +37.31% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $379.42 | -42.02% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $196.34 | +57.89% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $149.83 | -46.61% | 3 | Jul 11, 2017 |
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $34.26
Upside: +22.59%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $474.52
Upside: -8.96%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $4.84
Upside: +65.29%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $56 → $12
Current: $5.50
Upside: +118.18%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $67.91
Upside: -51.41%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.28
Upside: +2,087.50%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $27.45
Upside: -1.64%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $1.88
Upside: +272.34%
Prime Medicine
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $3.34
Upside: +648.50%
NuCana
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $2.06
Upside: +728,055.34%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.45
Upside: +1,624.14%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $25.49
Upside: +37.31%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $379.42
Upside: -42.02%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $196.34
Upside: +57.89%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $149.83
Upside: -46.61%